Evidence map›Paper›PMID 41226226›Full record

ReviewMolecules (Basel, Switzerland)2025

Marine Fungal Metabolites: A Promising Source for Antibiofilm Compounds.

Fadiah Ammar Almutairi, Ru Angelie Edrada-Ebel

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. An Alkaloid from MarinePharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Fadiah Ammar AlmutairiStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0NR, UK.
Ru Angelie Edrada-EbelStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0NR, UK.ORCID 0000-0003-2420-1117

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an urgent need for new alternative compounds with distinct modes of action due to the global rise in antibiotic resistance and the associated risks to public health. It is currently established that between 40 and 80% of bacterial biofilms cause antibiotic resistance. Furthermore, biofilm-forming bacteria are 1000 times more resistant to antibiotics than in their planktonic stages. Recently, the number of papers published on antibiofilm compounds from marine fungi has increased but relatively very slowly. Meanwhile, it has been proven that endophytic fungi can produce undiscovered compounds against bacterial biofilm. However, as shown in this review, there is still not enough attention given to highlight the relevance of intensifying studies amongst marine-derived fungi. Heren, we summarize the biologically active compounds isolated from marine-derived fungi and some marine fungal extracts tested against bacterial biofilms published from 2015 to 2024. Moreover, we disclose evidence on the scarcity of research on antibiofilm compounds from algal endophytic fungi. In addition, the primary approaches used in the hunt for bioactive secondary metabolites are covered. Included here are a few recent strategies described in the literature to optimize the production of antibiofilm-active fungal metabolites by employing such techniques involving media optimization, use of chemical elicitors, co-culture, and metabolic engineering.

Indexed as

Anti-Bacterial AgentsAquatic OrganismsBiofilmsBiological ProductsFungiBacteriaSecondary MetabolismAnti-Bacterial AgentsBiological Productsantibiofilmbiofilmco-cultureelicitorsendophytic fungimetabolitesseaweeds

Identifiers

PMID41226226
PMCPMC12610214

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.